A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers

Zydus Lifesciences

Status and phase

Completed

Phase 1

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: Placebo

Drug: ZYD1

Study type

Interventional

Funder types

Industry

Identifiers

NCT01972893

CTRI/2011/04/001684 (Other Identifier)

ZYD1/1001

Details and patient eligibility

About

ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV).

ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects. A first in human (FIH) Phase I study intends to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYD1 in normal healthy adult volunteers.

Enrollment

56 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age: 18-45 years
Mentally, physically, and legally eligible to give informed consent
Male and female volunteers weighing between 50-75 kg and 45-75 kg respectively
Ability to communicate effectively with the study personnel
Willingness to adhere to the protocol requirements
For gender effect study, only females with history of sterility or at least 1 year menopause or use of long acting nonhormonal contraceptive measures (e.g., intrauterine device) will be recruited.

Exclusion criteria

Presence or history of hypersensitivity to any of the active or inactive ingredients of ZYD1 formulation
Presence or history of pancreatitis at any time (Serum Amylase/Serum Lipase more than upper normal limit (UNL))
Presence or history of severe gastrointestinal disease in the last 6 months
Presence or history of renal insufficiency at any time (serum creatinine above the upper limit of the reference range)
Active liver disease and/or liver transaminases greater than 1.5 X UNL
Subject with personal or family history of medullary thyroid cancer
Subject with personal or family history of multiple endocrine neoplasia syndrome type 2
Subject with serum calcitonin >50 ng/L
History or presence of other systemic disorders or diseases (e.g., respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement)
Abnormal bleeding time (BT), clotting time (CT), prothrombin time (PT), and activated partial prothrombin time (APTT) tests on the day of check in
History or presence of any medication in the last 14 days including any medication known to interact with the Cytochrome P (CYP) 450 system
History or presence of significant alcoholism or drug abuse within the past 1 year
History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco products (more than 10 times per day)
Difficulty with donating blood
Systolic blood pressure more than 140 mmHg and less than 100 mmHg and diastolic blood pressure more than 90 mmHg and less than 60 mmHg
Pulse rate less than 60/minute and more than 100/minute
Any clinically significant abnormal X-ray or laboratory findings during screening
History or presence of any clinically significant electrocardiogram (ECG) abnormalities during screening
Major illness and/or major surgery in last 3 months
Volunteers who have participated in any drug research study other than the present trial within past 3 months
Volunteers who have donated one unit (350 ml) of blood in the past 3 months
For gender effect study, female volunteers with following criteria will not be recruited:
- History of pregnancy or lactation in the past 3 months
- Fertile female volunteers not protected against pregnancy by adequate long-term anti-fertility device or history of less than 1 year of menopause
- Using hormonal contraceptives
- Using hormone replacement therapy
- Unable to give assurance for protection against pregnancy for 3 months after the participation in this trial
- Positive urine pregnancy test on the day of check-in